12:00 AM
Mar 13, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Interferon-alpha: Phase II

AMAR said that its 89-patient, 3-month U.S. Phase II trial failed to show a statistically significant benefit of 150 IU/day or 50 IU/day interferon alpha in reducing morning stiffness associated with fibromyalgia compared to placebo. All three groups reported a reduction in...

Read the full 188 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >